TXG

10x Genomics, Inc.

Laboratory Analytical Instruments · SIC 3826CIK 1770787Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$643.0M

Net Income FY2025

$(44.0M)

EPS (Basic, as reported)

$-0.35

Net Margin FY2025

-6.8%

ROE FY2025

-5.5%

Total Equity

$796.0M

Shares Out

—

Business description

10x Genomics, Inc. — Laboratory Analytical Instruments. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 71 → 643 +31.7% CAGR

Fiscal yearFY2017FY2018FY2019⚑FY2020FY2021FY2022FY2023FY2024FY2025

Revenue71146246299490516619611643

Cost of revenue(11)(29)(61)(58)(74)(120)(209)(196)(199)

Gross profit61118185240416396409414444

Selling, general & administrative(47)(88)(131)(202)(258)(298)(343)(344)(316)

Total operating expenses(79)(228)(215)(775)(469)(564)(675)(609)(505)

Operating income(18)(111)(31)(534)(52)(168)(265)(195)(61)

Interest expense(1)(2)(3)(2)(1)0000

Interest & investment income013207171820

Other income (expense), net0(2)00(1)6171721

Pre-tax income(19)(112)(31)(534)(54)(162)(249)(178)(40)

Income tax expense000(8)(5)(4)(6)(5)(4)

Net income(19)(112)(31)(543)(58)(166)(255)(183)(44)

EPS — basic——($0.80)($5.37)($0.53)($1.46)($2.18)($1.52)($0.35)

EPS — diluted——($0.80)($5.37)($0.53)($1.46)($2.18)($1.52)($0.35)

Shares outstanding — basic (M)——39101110114117120125

Shares outstanding — diluted (M)——39101110114117120125

⚑ Weighted-average shares changed ×2.59 between FY2019 and FY2020 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.